MEMORANDUM

DATE: November 6, 2017

TO: Stacy Bigbie
   Associate Director, HSC Sponsored Projects Office

FR: Paul B. Roth, MD
    Chancellor for Health Sciences
    Dean, School of Medicine

RE: Industry-Sponsored Clinical Trial Indirect Cost Rate – 28%

As of October 9, 2017 the indirect cost recovery rate for all industry-sponsored clinical trials
(interventional and non-interventional) will continue to be the same, which is a minimum of 28
percent. This rate is considerable discount from UNMHSC’s normal federally approved indirect
rate and thus may not contain exclusions or F&A modifiers. All FSD trial costs will be billed at
‘Total Direct Costs’ (TDC), this includes non-interventional studies.

This indirect rate puts the UNM Health Sciences Center in accord with the majority of other
academic health institutions performing clinical trials across the country. This rate will remain
in effect for the foreseeable future.

A Clinical Trial is defined as the controlled, clinical testing in human subjects of
investigational new drugs, devices, treatments, or diagnostics or comparisons of approved
drugs, devices, treatments or diagnostics to assess their safety, efficacy, benefits, costs,
adverse reactions, and outcomes. Such studies may be conducted under an industry-developed
protocol or an investigator-developed protocol.